Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-11
2006-04-11
Low, Christopher S. F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S282000, C514S289000, C514S812000
Reexamination Certificate
active
07026329
ABSTRACT:
This invention relates to a method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist such as morphine and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of the bimodally-acting opioid agonist. The method of the present invention comprises administering to a subject an analgesic or sub-analgesic amount of a bimodally-acting opioid agonist such as morphine and an amount of an excitatory opioid receptor antagonist such as naltrexone or nalmefene effective to enhance the analgesic potency of the bimodally-acting opioid agonist and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of the bimodally-acting opioid agonist.
REFERENCES:
patent: 3332950 (1967-07-01), Blumberg et al.
patent: 3493657 (1970-02-01), Lewenstein et al.
patent: 3879555 (1975-04-01), Pachter et al.
patent: 4361553 (1982-11-01), Loh et al.
patent: 4457933 (1984-07-01), Gordon et al.
patent: 4582835 (1986-04-01), Lewis et al.
patent: 4760069 (1988-07-01), Rzeszotarski et al.
patent: 4769372 (1988-09-01), Kreek
patent: 4863928 (1989-09-01), Atkinson et al.
patent: 4882335 (1989-11-01), Sinclair
patent: 4889860 (1989-12-01), Rzeszotarski et al.
patent: 4910152 (1990-03-01), Meyers et al.
patent: 4935428 (1990-06-01), Lewis et al.
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5086058 (1992-02-01), Sinclair
patent: 5096715 (1992-03-01), Sinclair
patent: 5317022 (1994-05-01), Borsodi et al.
patent: 5321012 (1994-06-01), Mayer et al.
patent: 5352680 (1994-10-01), Portoghese et al.
patent: 5512578 (1996-04-01), Crain et al.
patent: 5580876 (1996-12-01), Crain et al.
patent: 5767125 (1998-06-01), Crain et al.
patent: 5834477 (1998-11-01), Mioduszewski
patent: RE36547 (2000-02-01), Crain et al.
patent: 6096756 (2000-08-01), Crain et al.
patent: 6362194 (2002-03-01), Crain et al.
patent: 85/50585 (1986-06-01), None
patent: 88/26432 (1989-06-01), None
patent: 88/18970 (1990-01-01), None
patent: 92/24023 (1993-02-01), None
patent: 144243 (1985-06-01), None
patent: 319243 (1989-06-01), None
patent: 352361 (1990-01-01), None
patent: 415693 (1991-03-01), None
patent: WO 87/01703 (1987-03-01), None
patent: 9406426 (1994-03-01), None
patent: WO 94/06426 (1994-03-01), None
patent: WO 95/03804 (1995-02-01), None
patent: 9503804 (1995-09-01), None
Cepeda MS et al., entitled “Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and oploid requirement but decreased incidence of oploid side effects,” Pain 107: 41-46, 2004.
Gan TJ et al., entitled “Opioid-sparing Effects of a Low-dose infusion of Naloxone in Patient-administered Morphine Sulfate,” Anesthesiology 87:1075-81, 1997.
Joshi GP et al., entitled “Effects of Prophylactic Nalmefene on the Incidence of Morphine-related Side Effects in Patients Receiving Intravenous Patient-controlled Analgesia,” Anesthesiology 90: 1007-11, 1999.
Kayser V et al., entitled “Cross-tolerance between analgesic low doses of morphine and naloxone in arthritic rats,” Brain Research, 405: 123-129, 1987.
Berkow, Robert et al., The Merck Manual of Diagnosis and Therapy, 16th Edition, Merck & Co. Inc., NY 1992 pp. 1558-1559.
Reynolds, JEF Martindale, The Extra Pharmacopoeica, 30th Ed., The Pharmaceutical Press, London, 1993, pp. 687-688.
Datta, et al., Peptides, vol. 3, pp. 433-437, 1992.
Tremblay, et al., Psychopharmacology, vol. 49, pp. 41-48, 1976.
Shen and Crain, Brain Research, vol. 636, pp. 286-291, 1994.
Dum and Herz, 1981, “In vivo Receptor Binding of the Opiate Partial Agonist, Buprenorphine, Correlated with its Agonistic and Antagonistic Actions,” Br. J. Pharmac. 74:627-633.
Budd, 1987, “Clinical use of opioid antagonists,” Balliere's Clinical Anesthesiology 1(4):993-1011.
Goodman & Gilman, 1975, The Pharmacological Basis of Therapeutics, 5th Edition, Macmillan, New York, Chapter 15, p. 273.
Crain & Shen, 1995, Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic co-treatment. Proc. Natl. Acad. Sci. U.S.A. Nov. 7, 1995, ;92(23):10540-10544.
Konieczko et al. 1988, “Antagonism of morphine-induced respiratory depression with nalmefene,” Br. J. Anaesth. 61:318-323.
Barsan et al. 1989, “Duration of Antagonistic Effects of Nalmefene and Naloxone in Opiate-induced Sedation for Emergency Department Procedures,” J. Emerg. Med. 7(2); 155-161.
Abu-Elheiga et al. 2001, “Continuous fatty acid oxidation and reduced fat storage in mice lacking Acetyl-coA carboxylase 2,” Science 291:2613-16.
Goodman & Gilman (eds.), 1975, The Pharmacological Basis of Therapeutics, 5th Edition, Macmillan, New York, Chapter 15, “Narcotic Analgesics and Antagonists” (by J.H. Jaffe and W.R. Martin) pp. 245-283.
Budd K., 1985, “The use of the opiate antagonist, naloxone, in the treatment of intractable pain.” Neuropeptides. 5(4-6):419-22.
Attal et al. 1989, “Behavioural evidence for a bidirectional effect of systemic naloxone in a model of experimental neuropathy in the rat.” Brain Res. 494(2):276-84.
Kayser et al. 1981, “Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats.” Brain Res. 226(1-2):344-8.
Kayser et al. 1984, “Further evidence for a bidirectional effect of naloxone on the pain threshold in tolerant and non-tolerant arthritic rats.” Neuropeptides. 5(1-3):49-52.
Malaise & Franchimont, 1987, “Methods of clinical and biological assessment of rheumatoid arthritis.” Scand. J. Rheumatol. Suppl. 65:81-4, Review.
Specification of U.S. Appl. No.
Shen and Crain,Regulatory Peptides, in press (1993).
Shen and Crain,Brain Research, 597:74-83 (1992).
Shen and Crain,Brain Research, 575:13-24 (1992).
Wang, et al.,Chinese J. Pharm. Toxical., 6:36-40 (1992) and English translation thereof.
Bo-Yi, Quin,New Drugs and Clinical Remedies, 12:119-123 (1992) and English translation thereof.
Lange, et al.,Toxicol. Applied. Pharm., 54:177-186 (1980).
Terwillinger, et al.,Brain Research, 548:100-110 (1991).
Shen, et al.,Brain Research, 559:130-138 (1991).
Crain and Shen,Trends Pharmacol. Sci., 11:71-81 (1990).
Fujimoto, et al.,Neuropharmacol., 29:609-617 (1990).
Shen and Crain,Brain Research, 531:1-7 (1990).
Shen and Crain,Brain Research, 491:227-242 (1989).
North,Trends Neurosci., 9:114-117 (1986).
Magnan, et al.,Nauyn-Schmiedelberg's Arch. Pharmacol., 319:197-205 (1982).
Bentley and Hardy,J. American Chem. Soc., 89:3281-3286 (1967).
Bentley and Hardy,Proc. Chem. Soc., p. 220 (1963).
Holmes and Fujimoto,Anesth. Analg., 77:1166-1173 (1993).
Miaskowski and Levine,Brain Research, 596:41-45 (1992).
Vaccarino, et al.,Pain, 36:103-109 (1989).
Cappell, et al.,Pharmacology Biochemistry&Behavior, 34:425-427 (1989).
Gardner,Substance Abuse, 2d ed., pp. 70-99 (1992).
Shen and Crain,Brain Res., 636:286-297 (1994).
Greenstein, et al.,Subst. Abuse, 2d ed., pp. 562-573 (1992).
Gonzales, et al.,Drugs, 35:193-213 (1988).
Shen and Crain,J. Neurosci., 14:5570-5579 (1994).
Blane, et al.,Brit. J. Pharmacol. Chemother., 30:11-22 (1967).
Fujimoto, et al.,J. Pharm. Exp. Ther., 251:1045-1052 (1989).
Gillman, et al.,Intern. J. Neurosci., 48:321-324 (1989).
Gillman, et al.,J. Neurol. Sciences, 49:41-49 (1981).
Gillman, et al.,South African J. Science, 83:560-563 (1987).
Pederson, et al.,Brit. J. Anaesth., 57:1045-1046 (1985).
Schmidt, et al.,Anesthesia, 40:583-586 (1985).
Bergman, et al.,Arch. Int. Pharmacodyn., 291:229-237 (1988).
Levine, et al.,J. Clin. Invest., 82:1574-1577 (1988).
Crain and Shen,J. Pharmacol. Exp. Ther., 260:182-186 (1992).
Goldberg, et al.,Science, 166:1548-1549 (1969).
Lasagna,Proc. Royal Soc. Med., 58(11):978-983 (1965).
Taiwo, et al.,J. Pharm. Exp. Therapeutics, 249:97-100 (1989).
Arts, e
Crain Stanley M.
Shen Ke-fei
Albert Einstein College of Medicine of Yeshiva University
Amster Rothstein & Ebenstein LLP
Jagoe Donna
Low Christopher S. F.
LandOfFree
Method of simultaneously enhancing analgesic potency and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of simultaneously enhancing analgesic potency and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of simultaneously enhancing analgesic potency and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3615060